Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients
- 1 July 1989
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 26 (3), 239-249
- https://doi.org/10.1016/0006-3223(89)90036-x
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patientsNeuropsychopharmacology, 1987
- Plasma Haloperidol and Clinical ResponseJournal of Clinical Psychopharmacology, 1987
- Reduced haloperidol and haloperidol: Effects on homovanillic acid in caudate and prefrontal cortexBiological Psychiatry, 1987
- Brief debrisoquin administration to assess central dopaminergic function in childrenLife Sciences, 1986
- Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brainNeuropharmacology, 1985
- Plasma Homovanillic Acid Concentration and the Severity of Schizophrenic IllnessScience, 1985
- Rapid Formation of Reduced Haloperidol in Guinea Pigs Following Haloperidol AdministrationActa Pharmacologica et Toxicologica, 1985
- Neuroleptic-Induced Decrease in Plasma Homovanillic Acid and Antipsychotic Activity in Schizophrenic PatientsScience, 1984
- Rapid and Simple Determination of Homovanillic Acid in Plasma Using High Performance Liquid Chromatography with Electrochemical DetectionActa Pharmacologica et Toxicologica, 1983
- Plasma homovanillic acid as an index of brain dopamine metabolism: Enhancement with debrisoquinLife Sciences, 1983